Amylyx Pharmaceuticals (Nasdaq:AML) has won FDA approval for Relyvrio (AMX0035; sodium phenylbutyrate and ursodoxicoltaurine), notching the first win for amyotrophic lateral sclerosis (ALS) in five years. The drug received Health Canada approval in June. The drug is known as Albrioza in that country. In a summary, FDA reviewers note that the limited clinical data available…